Tempus AI, Inc. (TEM) company profile

Tempus AI, Inc. develops technology and healthcare solutions centered on data-driven medicine. Through its operating areas, which include Diagnostics, Data and Applications, and AI Applications, the enterprise provides genomics testing services, insights, clinical trial solutions, and data licenses. The organization's offerings support healthcare providers, researchers, and life sciences entities by delivering testing capabilities alongside analytical data resources.

The company operates within domestic and international territories, conducting activities across regions that include Canada, Spain, and France, with property and legal jurisdiction spanning locations such as Washington and Pennsylvania. Tempus AI maintains its principal executive offices in Chicago, Illinois.

Summary of the business section of Tempus AI's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

“The initial public offering price is $37.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

“As of December 31, 2025, we had more than 3,800 employees, of which 1,232 were technical and were engaged in product and engineering, and research and development.”